Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H20ClN5O5 |
Molecular Weight | 421.835 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(OCCC2=CC=C(Cl)C=C2)=NC3=C1N=CN3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O
InChI
InChIKey=WUCQGGOGHZRELS-LSCFUAHRSA-N
InChI=1S/C18H20ClN5O5/c19-10-3-1-9(2-4-10)5-6-28-18-22-15(20)12-16(23-18)24(8-21-12)17-14(27)13(26)11(7-25)29-17/h1-4,8,11,13-14,17,25-27H,5-7H2,(H2,20,22,23)/t11-,13-,14-,17-/m1/s1
Sonedenoson (MRE0094) is a topical adenosine A2A-receptor agonist which was under clinical development for the treatment of for diabetic foot ulcer. The compound was originally developed by New York University, and licensed to Medco Research (King Pharmaceuticals). King Pharmaceuticals was acquired by Pfizer in 2010. Sonedenoson has been in phase II clinical trials for the treatment of chronic diabetic neuropathic foot ulcers. However, this research has been discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11936752
Application of Sonedenoson (MRE0094) (1 ug/wound and 10 ug/wound) achieved 50% wound closure significantly more rapidly than control application (day 1.9, 1.9, 3.5, 3.2, respectively, versus control day 4).
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15673602
TSP1 protein secretion was down-regulated after treatment with the A2A agonist in a dose-dependent manner (EC50 = 0.23 uM).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12443
Created by
admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
|
PRIMARY | |||
|
CHEMBL1950553
Created by
admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
|
PRIMARY | |||
|
131865-88-8
Created by
admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
|
PRIMARY | |||
|
DTXSID90157239
Created by
admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
|
PRIMARY | |||
|
9910098
Created by
admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
|
PRIMARY | |||
|
TT-03
Created by
admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
|
PRIMARY | |||
|
8928
Created by
admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
|
PRIMARY | |||
|
C84176
Created by
admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
|
PRIMARY | |||
|
300000034409
Created by
admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
|
PRIMARY | |||
|
2OT4KAG5JL
Created by
admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
|
PRIMARY |
ACTIVE MOIETY